Journal: Therapeutic Advances in Medical Oncology

Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

doi: 10.1177/17588359251348310

Figure Lengend Snippet: Network diagrams of comparisons on different treatments. Direct comparisons are represented by the colored lines connecting the treatments. Line width is proportional to the number of trials, including every pair of treatments, whereas circle size is proportional to the total number of patients for each treatment in the network. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm + anlo, Benmelstobart + anlotinib; Durv, Durvalumab; Nivo, Nivolumab; Pemb, Pembrolizumab; Pla, placebo; Serp, Serplulimab; Tira + atez, Tiragolumabz + atezolizumab; Tisl, Tislelizumab; Tori, Toripalimab.

Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

Techniques:

Journal: Therapeutic Advances in Medical Oncology

Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

doi: 10.1177/17588359251348310

Figure Lengend Snippet: HRs, ORs, and their 95% confidence intervals from network meta-analysis of different first-line therapeutic regimens in ES-SCLC patients. (a) HRs and 95% CI for overall survival (upper triangle in yellow) and progression-free survival (lower triangle in green). The hazard ratio < 1.00 provides better survival benefits. (b) ORs and 95% CI for objective response rate (upper triangle in yellow) and grade ⩾ 3 adverse events (lower triangle in green). OR < 1.00 indicates a better efficacy or more toxicity. The results are presented as column-defined treatment versus row-defined treatment. Significant results are in bold. Adeb, Adebrelimab; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Chemo, Chemotherapy; CI, confidence intervals; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; HR, hazard ratios; Nivo, Nivolumab; OR, odds ratio; Pemb, Pembrolizumab; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

Techniques:

Journal: Therapeutic Advances in Medical Oncology

Article Title: Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis

doi: 10.1177/17588359251348310

Figure Lengend Snippet: Bayesian ranking profiles of comparable treatments on efficacy and safety for ES-SCLC patients. Ranking plots indicate the probability of each comparable immunotherapy combination being ranked from first to last on OS, PFS, ORR, and grade ⩾ 3 AEs. Adeb, Adebrelimab; AE, adverse event; Atez, Atezolizumab; Atez-beva, Atezolizumab + bevacizumab; Benm-anlo, Benmelstobart + anlotinib; Durv, Durvalumab; ES-SCLC, extensive-stage small-cell lung cancer; Nivo, Nivolumab; ORR, overall response rate; OS, overall survival; Pemb, Pembrolizumab; PFS, progression-free survival; Serp, Serplulimab; Tisl, Tislelizumab; Tori, Toripalimab.

Article Snippet: A small-molecule and a multitarget TKI, Anlotinib, has indicated an increased OS of 2.4 months when applied as a later-line therapy for ES-SCLC patients compared to placebo., Therefore, NMPA has recommended anlotinib as a third-line or subsequent-line treatment option for ES-SCLC patients.

Techniques: